Saving the lives

of humans and animals

Our goal in founding Detraxi was to enhance organ preservation and cell culturing at room temperature and through cryopreservation. As our studies involving cells, tissues, and organs proceeded, it became clear that our proprietary technology had far broader applications and led us to develop novel therapies for the well-being of both humans and animals.

we are addressing

The challenges

One of the greatest challenges facing
emergency response teams is the
immediate availability of
the right blood type,

enabling patients to be stabilized for
long enough to receive treatment for
what can be survivable injuries.

The use of blood-based
products is the only
solution to
date for severe
blood loss.

The average waiting time for a
deceased donor kidney transplant
is approaching 3 years, and that for
heart transplants 18 months.

Each year, more patients are placed on the waiting lists
than receive transplants, causing the waiting time to
increase. With such constraints, preservation of organs
for transport between centers is crucial.

A key constraint in tissue and
organ transplants is that
the preservative
solutions have barely
on since their
development in the late 1980's.

The critical issue with organ engineering
outside of the body is the limited
availability of human cells,

a suitable matrix with the same composition
and architecture of the target tissue, and
the ability to maintain the
viability of the organ without a blood supply.

Prepared stem cells are currently
being frozen in order to preserve
However, the temperature which frozen
cells are stored will affect their viabilitu. for example,
storage at-80oC may permit slow chemical reactions
(due to small amounts of unfrozen water). which will
eventually result in cell death.

Formaldehyde, a highly toxic poison, is
used as a 10% neutral buffered formalin,
the most widely used universal
fixative for preserving
organs and tissues.

An alternatives to Formaldehyde is
Clutaraldehyde, which although
widely used as a fixative for
standard electron microscopy.
has a slow penetration, needs periodic purification to
maintain functional aldehyde levels and therefore is
greatly limited as a bilogical fixative.

Therapeutic Areas

Blood Bridge (Fluid Replacement)

With blood transfusions in humans and animals, common issues that arise are the constant need for each specific blood type and the fact that donated blood only remains viable for 40 days.


Tissue samples are used to diagnose health disorders and diseases, however, currently tissue samples are being preserved with fixative agents such as formalahyde - this greatly affects the sample quality in a negative way.

Tissue & Organ Transplantation

Advancements in preservative solutions for tissue and organ transplations have barely moved on from the University of Wisconsin solution developed in the late 1980s.

Regenerative Medicine

Tissue engineering, cellular therapies and the development of medical devices and artificial organs are revolutionary in the medical field as their advancements are helping to save more and more lives.


Associated with

Detraxi Registered with the Small Business Innovation Research (SBIR) Program
September 11, 2018

Detraxi is now registered with the Small Business Innovation Research (SBIR) Program.

Replacing the need for donated with bioengineered organs
August 16, 2018

It’s pretty shocking to hear that “Every 30 seconds a patient dies from diseases

Detraxi have the pleasure of welcoming Veronik Dasys to the team
August 8, 2018

Detraxi have the pleasure of welcoming Veronik Dasys to the team

Life Science & Technology Hub July 31 Fort Lauderdale, Florida
August 1, 2018

Tatiane Berdum, VP of Strategic Business Development, attended the Life Science & Technology Hub.